New antithrombotic agents: An overview

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 1, 1997, Pages 85-96

  Windstetter, U ^a   Huber, K ^b   Gulba, D C ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ARGINYLGLYCYLASPARTIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTROBAN; DESULFATOHIRUDIN; DEXTRO PHENYLALANYLPROLYLARGININAL; DIPYRIDAMOLE; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LAMIFIBAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; SERINE PROTEINASE INHIBITOR; THROMBIN INHIBITOR; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; TRAPIDIL; TRIGRAMIN; UNINDEXED DRUG;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; INTRAVASCULAR CATHETER; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RASH; RESTENOSIS; SITE DIRECTED MUTAGENESIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030697242     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80030-6     Document Type: Conference Paper

References (31)

1. Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-481.
2. Simoons M L, Deckers J W. New directions in anticoagulant and antiplatelet treatment. Br Heart J 1995; 74: 337-340.
3. Harker L A, Hanson S R, Kelly A B. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-472.
4. Antiplatelet trialists' collaboration: Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
5. Gersh B J, Opie L H. Antithrombotic agents: Platelet inhibitors, anticoagulants, and fibrinolytics. In: L H Opie (ed). Drugs for the heart. W B Saunders, Philadelphia, USA, 1995.
6. Stassen J M, Lambeir A-M., Vreys I, Deckmyn H, Matthyssens G, Nyström A, Vermylen J. Characterization of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. Thromb Haemost 1995; 74: 655-659.
7. Pietrolungo J F, Topol E J. Thrombolytic and new antiplatelet agents. In: S G Ellis and D R Holmes (eds). Strategic approaches in coronary intervention. Williams & Wilkins, Baltimore, USA, 1996.
8. Schömig A, Neumann F J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
9. Hirsh J. Heparin. N Engl J Med 1992; 324: 1565-1574.
10. Fenton II J W. Thrombin functions and antithrombotic interventions. Thromb Haemost 1995; 74: 493-498.
11. Weitz J I, Hirsh J. Antithrombins: their potential as antithrombotic agents. Annu Rev Med 1992; 43: 9-16.
12. Vermylen J. Clinical trials of primary and secondary prevention of thrombosis and restenosis. Thromb Haemost 1995; 74: 377-381.
13. Serruys-P W, Herrman-J P, Simon-R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333(12): 757-763.
14. Becker R C, Cannon C P, Tracy R P, et al. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in hospital clinical events in unstable angina and non Q wave myocardial infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J 1996; 131: 421-433.
15. Kaiser B, Fareed J, Walenga J M, Hoppensteadt D, Markwardt F. In vitro studies on thrombin generation in citrated, rhirudinized and heparinized whole blood. Thromb Res 1991 ; 64: 589-596.
16. Lefkovits J, Topol E J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536.
17. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome N O, Berry C N. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-160.
18. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-639.
19. Noeske-Jungblut C, Haendler B, Donner P, Alagon A, Possani L, Schleuning W D. Triabin, a highly potent exosite inhibitor of thrombin. J Biol Chem 1995; 270(48): 28629-28634.
20. Rapaport S I, Rao L V M. The tissue factor pathway: How it has become a 'prima ballerina'. Thromb Haemost 1995; 74: 7-17
21. Broze GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
22. Brass L F. Issues in the development of thrombin receptor antagonists. Thromb Haemost 1995; 74: 499-505.
23. Weksler B B, Pett S B, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800-805.
24. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound guided stent implantation. Circulation 1996; 93(2): 215-222.
25. Blengino S, Maiello L, Hall P, Nakamura S, Martini G, Colombo A. Randomized trial of coronary stent implantation without anticoagulation: aspirin vs ticlopidine. Circulation 1994; 90(Suppl): I-124.
26. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123: 1439-1444.
27. Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, et al. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem 1991; 34: 3114-3125.
28. Lefkovits J, Plow E F, Topol E J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
29. Coller B S, Anderson K, Weisman H F. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-308.
30. Coller B S, Peerschke E I, Scudder L E, Sullivan C A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins lib and/or IIIa. J Clin Invest 1983; 72(1): 325-338.
31. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.